With a slashed valuation the newly listed biotech heads for phase 3.
ApexOnco Front Page
Recent articles
An actinium-based backup and Werner helicase inhibitor are notable absences.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
As pivotal data approach, the French group pays $210m for ex-US rights.
